<DOC>
	<DOCNO>NCT00411099</DOCNO>
	<brief_summary>This study ass efficacy , safety tolerability agomelatine ( AGO178 ) 25 mg 50 mg patient Major Depressive Disorder ( MDD ) . This study include 8-week double-blind phase 52-week open-label phase .</brief_summary>
	<brief_title>Efficacy , Safety Tolerability Agomelatine Treatment Major Depressive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>S 20098</mesh_term>
	<criteria>Diagnosis Major Depressive Disorder , single recurrent episode , accord DSMIV criterion HAMD17 total score &gt; = 22 Screening Baseline CGISeverity score &gt; = 4 Screening Baseline Only patient complete core protocol eligible participate OpenLabel Extension Phase History bipolar disorder ( I II ) , schizophrenia , schizoaffective disorder , eat disorder , obsessive compulsive disorder Any current Axis I disorder major depressive disorder focus treatment Substance alcohol abuse last 30 day , dependence last 6 month Concomitant psychotropic medication , include herbal preparation melatonin Psychotherapy type Female patient childbearing potential use effective contraception Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>agomelatine , major depressive disorder , MDD , depression</keyword>
</DOC>